The finding of a genetically linked polymorphic DNA marker has made possible a predictive test for Huntington's chorea. This
many of those at risk will not know their genetic state until after they have completed their family, and non-carriers have to wait until late middle age before they can be reasonably certain of freedom from the threat of developing the disease themselves.
A predictive test to detect carriers of the Huntington's chorea gene before the onset of symptoms would offer several advantages to those at risk. Non-carriers would be freed from fear of developing the disease and the stigma attached to those at risk. They would no longer have the responsibility of deciding whether to abstain from procreation or seek abortions to break the chain of transmission. Efforts have been made for many years to find such a test. Previous candidates such as the levodopa provocation test proved unreliable,23 and debate to establish guidelines for predictive testing was called for before such testing became possible. 4 The finding by Gusella and colleagues of a polymorphic DNA marker genetically linked to Huntington's chorea has now made possible a predictive test for people at risk,' although this DNA probe (designated G8) has so far been used only for research. Indeed, the probe was distributed to laboratories on the understanding that investigators would not make use of it for clinical purposes without prior discussion with Dr Gusella. Much evidence confirming the linkage of G8 to Huntington's chorea has been accumulated since the finding of G8, and some clinicians now wish to use it for predictive testing. This has been controversial,`9 and before the G8 probe is used clinically the ethics of predictive testing need to be clarified.
Ethical issues
In practice the predictive test is likely to give rise to ethical problems of three types. The first concerns the accuracy of the test and the possibility of inaccurate predictions. The second (and arguably most serious) concerns the possibility that some of those identified as probable gene carriers will be unable to cope with the burden of this knowledge. Finally, we must consider the possible misuse of information gained from predictive tests.
ACCURACY OF PREDICTIONS
The information derived from predictive testing is used by those tested to make important decisions about their future lives, and it is therefore essential to There is here an analogy with the methods used to detect carriers of Duchenne muscular dystrophy, in which information from the pedigree structure, creatine kinase assays, and DNA probes is combined to give the best estimate of risk; these estimates, although imperfect, are used as the basis for profound decisions on reproduction including termination of pregnancy. Furthermore, the remaining small element of uncertainty has the merit of leaving a little hope for those predicted to have a very high risk.
Predictive testing promises clear benefits to those found not to be gene carriers, and these will be in a majority because testing will be sought only by those still at risk who are not already affected; these have a maximum risk of 50%, but many will start from a 25% risk. The benefits to this majority, however, must be balanced against the possibility of harm to the remainder, who will be identified as probable carriers of Huntington's chorea; but these too will at least have a solid foundation on which to make decisions for the future, and this must also be taken into account.
THE BURDEN OF KNOWLEDGE AND THE RISK OF SUICIDE
Predictive testing for Huntington's chorea promises great benefits to those who prove not to be carriers, but it has been suggested that those shown to be carriers will be deprived of hope and will be at greatly increased risk of depression and suicide.'4 The prevalence of psychiatric disorders is high in those who subsequently develop Huntington's chorea,"' 16 and there is an increased prevalence of suicide in some families at risk. '7 In the United States the relative risk of a death being due to suicide is much higher in those with diagnosed or suspected Huntington's chorea than in the general population,' although this finding was not confirmed by a recent study from Norway."9 Some of these studies were conducted before the advent of standardised methods of diagnosis and used subjects ascertained from 
Code of practice
In view of these potential problems it is important to develop a code of practice for predictive testing (and this need will extend to other diseases in the future). For example, it might be held that predictive testing should not be offered to minors or used in cases in which it would determine the carrier state of a relative who did not wish to know. It has also been argued that insurance companies and others with a financial interest should be precluded by law from asking for information on carrier state.33 Other problems might be prevented by careful counselling before testing to ensure that the person understands the meaning and limitations of the results and by providing adequate support after testing to enable the person to adjust to the new knowledge. Skilled counselling would be essential to ensure as far as possible that testing took place only with the fully informed consent of the person concerned, free of any external pressures.
Conclusion
What is now required is a prospective study of the psychological and social consequences ofpredictive testing to evaluate the benefits and hazards and if possible to identify characteristics that help to forecast whether a person will be able to react constructively to the result. This would have the additional virtue ofacting as a paradigm for similar problems that will surely arise after the application of new predictive methods to other and perhaps more common diseases.
A study would inevitably expose the subjects to some risks, but this does not give rise to any novel ethical problems,' and it is for people to decide for themselves whether they wish to undergo predictive testing. Informed consent is essential, and it should be recognised that some people will adopt an altruistic attitude in seeking to protect their future progeny. Ethical approval should be given only to investigators who ensure that all subjects are provided with sufficient support and psychiatric supervision after testing so that it is possible to detect any psychopathology at an early stage and to intervene to minimise any further damage. Long term support for those identified as carriers ofthe gene will be required, and research designs will need to allow for this to continue long after data collection has been completed. In view of this need for long term support as well as the difficulty of obtaining a sample large enough to produce meaningful results, clinical trials of predictive testing will need to be carried out by those centres that already have experience with established genetic registers as a clinical and support service rather than simply as a research resource. These centres will already have identified subjects who have the necessary pedigree structure for predictive testing, and these subjects will be well known to the support staff attached to the register. A preexisting relationship with staff maintaining a genetic register coupled with formal psychiatric evaluations and close participation by general practitioners will offer the best prospect of detecting problems early enough to prevent serious consequences.
More accurate predictive tests for Huntington's chorea will probably become available, but this is not an argument for delay because more precise tests will leave less residual hope for those identified as carriers of the gene and we will be in even greater need ofguidelines. Debate is clearly required to evolve guidelines for the clinical applicatiion of these new techniques, but this must be informed by the results of preliminary clinical trials. The time is ripe for these to begin.
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What is the present attitude on the efficacy of lithium as treatment for manic depression and depressions ofother aetiology?
The use of lithium salts in the management of mood disorders has been one of the most rewarding therapeutic strategies in psychiatry. There is overwhelming evidence for their efficacy, and the morbidity of recurrent affective disorders has been substantially reduced.' In acute mania lithium is as effective as neuroleptic medication (phenothiazines and butyrophenones) and has the advantage that patients do not experience the "straight jacket" effect associated with neuroleptic medication. Moreover, lithium is less likely to cause the serious unwanted effect of tardive dyskinesia associated with the long term use of neuroleptic medication. As an antidepressant it is probably less effective than conventional antidepressants (tricyclics and monoamine-oxidase inhibitors) but is an effective adjunct to these antidepressants in patients with resistant depressions.2 There is a clear trend for patients with bipolar depressions-that is, acute depression in a patient who had suffered a previous episode of mania-to have a more favourable response than patients with depression without such a history. Lithium salts, however, have been mainly used as prophylactic treatment in the management of bipolar (depression alternating with mania) and unipolar (recurrent depression) illness. In unipolar patients it is particularly effective in those with an endogenous profile of symptoms, patients with a positive family history of depression, and those who had shown less personality disturbance before the onset of their first episode of illness. Patients with unipolar illness with a non-endogenous profile of symptoms (neurotic depression) may benefit from lithium if it was combined with psychological treatment, particularly cognitive therapy.-M T ABOU-SALEH, senior lecturer in psychiatry, Liverpool. 
